Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.62 |
| ▸ | OPRL1 | P41146 | 15/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409654 | 0.86 | OPRM1 (0.76) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3407602 | 0.79 | OPRM1 (0.55) | OPRM1OPRL1OPRK1 | |
| SCHEMBL23778868 | 0.77 | OPRM1 (0.51) | OPRM1OPRL1USP2TP53ALOX15 | |
| SCHEMBL17444269 | 0.77 | OPRM1 (0.58) | OPRM1OPRL1TSHRMAPK1 | |
| SCHEMBL3413497 | 0.76 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3410403 | 0.75 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3410725 | 0.75 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3410993 | 0.73 | OPRM1 (1.00) | OPRM1OPRL1OPRK1 | |
| Hydrogen Peroxide SCHEMBL28248196 | 0.73 | ALDH1A1 (0.62) | USP2TP53ALOX15TSHRMAPK1 | |
| SCHEMBL161322 | 0.71 | ALDH1A1 (0.59) | USP2TP53ALOX15TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | claimed |
| US-8835689-B2 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2014-09-16 | — | — | US | claimed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | claimed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | claimed |
| EP-2502907-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2018-08-29 | — | — | EP | disclosed |
| EP-2518052-B1 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9580386-B2 | Substituted 4-aminocyclohexane derivatives | GRÜNENTHAL (DE) | 2017-02-28 | — | — | US | disclosed |
| US-9403767-B2 | Substituted 4-aminocyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8835689-B2 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2014-09-16 | — | — | US | disclosed |
| EP-2260021-B1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | Grünenthal GmbH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2518052-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2502907-A1 | Substituted 4-aminocyclohexane derivatives | Grünenthal GmbH (DE) | 2012-09-26 | — | — | EP | disclosed |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | GRUNENTHAL GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357634-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885USP2 3464/4885 |
| US-20090247530-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885USP2 3464/4885 |
| US-20120202810-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885USP2 3464/4885 |
| US-20130197095-A1 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES | OPRL1, OPRK1, OPRD1 | OPRM1 4/4885OPRL1 1/4885USP2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.